SureTrader
Interactive Brokers Advertisement
SureTrader
Home > Boards > US OTC > Biotechs >

Advanced Environmental Petroleum (AEPP)

AEPP RSS Feed
Add AEPP Price Alert      Hide Sticky   Hide Intro
Moderator: reaper247, B0tt0M WaTcH3R, Eltp, fuzzymcilwoods, FIN85, ninersax
Search This Board: 
Last Post: 6/24/2017 4:45:30 PM - Followers: 139 - Board type: Free - Posts Today: 14

 

BIOTECH Merger in Action


April 24 Interview with CEO Michael Redman
 


On April 6, 2017, in connection with the change of control of the Company, Mr. Kistler resigned as the Company’s sole director, executive officer and other positions and Mr. Redman was appointed a director and our chief executive officer and president and J. Donald Payne as a director and our Secretary and chief accounting officer of the Company.



Verified Company Profile  4/10/2017
Email: mredman@oncolixbio.com
 

AEPP (Advanced Environmental Petroleum Producers) Oncolix, Inc. has become the controlling shareholder

https://www.sec.gov/Archives/edgar/data/1574061/000147793217001787/aepp_sc13d.htm
https://www.sec.gov/Archives/edgar/data/1584137/000147793217001656/aepp_8k.htm



AEPP enters into a SPA (Share Purchase Agreement) with Oncolix, Inc. 


Initial agreement was made on March 7, 2017
http://ih.advfn.com/p.php?pid=nmona&article=74041605

http://ih.advfn.com/p.php?pid=nmona&article=74093500

Merger expected to be finalized on or around April 3, 2017
http://ih.advfn.com/p.php?pid=nmona&article=74157198

AEPP UPDATE:

Change of control of AEPP has been filed with the Florida Secretary of State showing Oncolix CEO

Michael Redman and Oncolix director, Donald Payne as controlling officers of AEPP.

 
AEPP Security Details
Share Structure
  Market Value1 $3,571,704 a/o Apr 07, 2017
Authorized Shares 500,000,000 a/o Mar 30, 2017
Outstanding Shares 93,911,633 a/o Apr 04, 2017
  -Restricted Not Available
  -Unrestricted Not Available
  Held at DTC Not Available
  Float 33,311,633 a/o Apr 06, 2017
  Par Value Not Available
Transfer Agent(s) Verified by Transfer Agent
VStock Transfer LLC
Shareholders
Shareholders of Record 101 a/o Apr 06, 2017

 


Zero outstanding debt

"approximately $111,928 of the $315,000 purchase price will be utilized by the Seller to pay all outstanding indebtedness and financial obligations of the Company so that immediately following the closing of the Share Acquisition (the “ SPAClosing ” ), the Company will have no outstanding indebtedness and/or other financial obligations."
http://ih.advfn.com/p.php?pid=nmona&article=74093500 

April 3, 2017 SPA closing date expected
Due to unanticipated circumstances, the mailing did not occur. As a result, we filed Amendment No. 1 to the Original Filing on March 21, 2017, ( “ Amendment No.1 and together with the Original Filing, collectively, the “ Information Statement ” ), anticipate March 22, 2017 to be the new mailing date and the date of the Board Change and the SPA Closing to occur on or about April 3, 2017 (but in no event earlier than 10 days after the actual mailing date).

Filings from Oncolix after closing will be expected within 4 business days which will detail merger.
Consequently, many more news events will follow with Oncolix releasing details of their business and status of Prolanta as it goes through FDA clinical trials.


 

Who is Oncolix, Inc.?

https://oncolixbio.com

April 2017 Company Presentation:
https://nebula.wsimg.com/8b544fcbb6f5bf5fb52c1c7e5a69eb81?AccessKeyId=D34B304F5C474C27E878&disposition=0&alloworigin=1

POST ACQUISITION INTERVIEW WITH CEO MICHAEL REDMAN

https://www.youtube.com/watch?v=Ox6n1HH8v_0&feature=youtu.be
 

Oncolix, Inc. (Oncolix) is a clinical-stage bio-pharmaceutical company based in Houston, Texas. We are developing Prolanta™, a targeted therapeutic protein for the treatment of ovarian, breast and other cancers. The Company has a US FDA-cleared IND to commence human testing of Prolanta™ in our first indication, the treatment of ovarian cancer.  This clinical trial is expected to begin in late 2015. Prolanta™ is a prolactin receptor antagonist that has demonstrated significant efficacy in xenograft models through a unique mechanism of action, autophagy (see Our Science). In addition to ovarian cancer, there is strong preclinical evidence Prolanta™ will be effective in breast, prostate and other cancers.   

The FDA has also approved the designation of 
Prolanta™ as an Orphan Drug for the treatment of ovarian cancer, which may allow an accelerated regulatory approval by the FDA, reduced filing fees, federal tax credits and marketing exclusivity. 

Prolanta is currently in FDA clinical trials phase 1. 
https://clinicaltrials.gov/ct2/show/NCT02534922

Oncolix received Orphan Drug Status for their developmental drug Prolanta.
http://www.bizjournals.com/houston/news/2013/04/24/oncolix-poised-to-start-phase-i-trials.html

8 U.S. Patents have been awarded in the development of Prolanta
http://oncolixbio.com/patents.html

 

PATENTS

The eight US Patents issued to Oncolix are listed in the following table. Non-US patents or applications are not listed.

Patent Number Issue Date Issued To Title
US 7,115,556 03 OCT 2006 Oncolix Use of Anti-Prolactin Agents to Treat Proliferative Conditions
US 7,201,905 10 APR 2007 Oncolix Bi-Functional Cancer Treatment Agents
US 7,339,027

US 8,304,381
4 MAR 2008

6 NOV 2012
Oncolix Human Prolactin Antagonist-Angiogenesis Inhibitor Fusion Proteins
US 7,632,809 15 DEC 2009 Oncolix Multimeric Ligands with Enhanced Stability
US 8,648,046

US 8,754,035
11 FEB 2014

17 JUN 2014
Oncolix Compositions and Methods for Visualizing and Eliminating Cancer Stem Cells
US 8,754,031 17 JUN 2014 Oncolix Use of Prolactin Receptor Antagonists in Combination with an Agent that Inactivates the HER2/neu Signaling Pathway

Notable excerpt from company website
Our initial focus is ovarian cancer, and we have an FDA-cleared Investigational New Drug (IND) application to commence a Phase I human trial. Based on our preclinical evidence of expected efficacy, the FDA has also granted Prolanta™ Orphan Drug status for the treatment of ovarian cancer.  Our collaborators at The University Texas MD Anderson Cancer Center developed the efficacy data in ovarian cancer, which was published in Cell Reports (see Scientific Publications). These researchers demonstrated that Prolanta™ has a novel mechanism of action, induced autophagy) against ovarian cancer, and also demonstrated the synergy of Prolanta™ with other chemotherapy drugs. See Ovarian Cancer and Prolanta™.

 

 

The Oncolix Team

Management

\

\

Board Members

\

\

\

Company Advisors

\

\

\



 



AEPP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AEPP News: Quarterly Report (10-q) 05/15/2017 06:12:06 AM
AEPP News: Initial Statement of Beneficial Ownership (3) 04/28/2017 11:44:59 AM
AEPP News: Initial Statement of Beneficial Ownership (3) 04/24/2017 02:16:03 PM
AEPP News: Statement of Beneficial Ownership (sc 13d) 04/17/2017 04:04:57 PM
AEPP News: Amended Statement of Changes in Beneficial Ownership (4/a) 04/14/2017 10:29:25 AM
PostSubject
#5270  Sticky Note New presentation up... AltJactUp 06/01/17 01:45:42 AM
#5061  Sticky Note AEPP/Oncolix summary. reaper247 05/30/17 01:52:40 AM
#4458  Sticky Note It's official. No Reverse Split. fuzzymcilwoods 05/15/17 04:41:18 PM
#3419  Sticky Note Reverse split is definitely happening. The wording in ninersax 04/11/17 10:53:11 PM
#6226   Management Team and Scientific Collaborations: Oncolix has assembled DayDreeming 06/24/17 04:45:29 PM
#6224   Who care about Kistler, lucky he don't steer B0tt0M WaTcH3R 06/24/17 02:41:20 PM
#6223   Wrong.. ALL are wrong.. B0tt0M WaTcH3R 06/24/17 02:39:31 PM
#6221   Lets recap....Here is what we know AEPP Brian laraz5 06/24/17 10:16:28 AM
#6220   King of Penny scams Brian Kistler sitting at laraz5 06/24/17 09:28:59 AM
#6218   REDMAN STEERING THE WHEEL.. NO SCAM HERE B0tt0M WaTcH3R 06/24/17 07:13:14 AM
#6216   A scam? LOL…Lets discuss facts again. reaper247 06/24/17 01:40:30 AM
#6215   Are you sure on that? reaper247 06/24/17 01:11:56 AM
#6214  Restored Don't feel bad, lots of shareholders have a laraz5 06/24/17 12:48:27 AM
#6213   Let look at the facts. reaper247 06/24/17 12:45:10 AM
#6211   FDMF,Launch T.V. the list goes on... getReady 06/23/17 05:51:55 PM
#6210   I'm having a hard time trying to decipher dabullishbear 06/23/17 05:44:32 PM
#6209   Greed, these Con men who run these empty laraz5 06/23/17 04:02:35 PM
#6208   Dilute to what??? No NOTE to convert boy.... B0tt0M WaTcH3R 06/23/17 02:50:40 PM
#6207   Watch out Brian King Con Kistler is involved laraz5 06/23/17 02:19:26 PM
#6205   HOUSTON, TX, April 6, 2017 / -- ONCOLIX, DayDreeming 06/23/17 10:17:56 AM
#6203   56 million more shares to dilute. This laraz5 06/23/17 09:40:13 AM
#6201   Bwahaha... busted.. never trust..... CLEARLY STATED ON LATEST B0tt0M WaTcH3R 06/23/17 06:31:12 AM
#6198   LOL laraz, reaper247 06/23/17 01:39:06 AM
#6197  Restored Wow ninersax. Did you read the filings? Zero reaper247 06/23/17 01:23:33 AM
#6196   Sooooo..... Now we have claims that this is a reaper247 06/23/17 12:46:21 AM
#6195   Tomorrow aepp gunna hit .08....and if it doesn't Pinky4 06/22/17 08:56:14 PM
#6194   Agree. Would be nice to get news CatfishHunter 06/22/17 08:23:13 PM
#6193   Fyi..interesting reading..reverse merger will happen soon and w/o tmcfo 06/22/17 07:45:32 PM
#6192   while AEPP is pending on price, DCTH was chromaticity 06/22/17 03:52:23 PM
#6191   Apparently you haven't read them either because your ninersax 06/22/17 02:19:41 PM
#6188   Did you read the filings? AEPP has zero debt... BLight1911 06/22/17 12:41:43 PM
#6184   To make it even worse AEPP diluted 10 laraz5 06/22/17 12:13:12 PM
#6183   LMFAO, AEPP is 100% debt free microcaptrdr24 06/22/17 12:01:03 PM
#6182   Oncolix needed an empty shell to sell worthless laraz5 06/22/17 11:58:22 AM
#6180   ROTFLMFAO!!!! That piece is from Nov 2016! CatfishHunter 06/22/17 10:54:48 AM
#6179   AEPP is a pump and dump scam who laraz5 06/22/17 10:42:38 AM
#6178   HOUSTON, TX, April 6, 2017 / -- ONCOLIX, DayDreeming 06/22/17 10:23:01 AM
#6175   Oncolix is a very real entity. And the Sage7243 06/22/17 09:48:29 AM
#6174   Who is "they" Are we creating some magical laraz5 06/22/17 09:15:43 AM
#6173   They do the samething at end of day Sungod95 06/22/17 09:09:14 AM
#6172   Which brokerage allows you to short penny stocks? laraz5 06/22/17 09:06:52 AM
#6171   SHORTS AFRAID TO SHORT "AEPP"!!! SHORT_VOLUME_RATIO_IS_ONLY_.074_PER_CHART_BELOW Rat Fink 06/21/17 10:57:36 PM
#6170   "AEPP" DEFINITELY "HOLDING" THEIR SHARES!!! ONLY_67,774_SHARES_VOLUME_TODAY!!! Rat Fink 06/21/17 10:06:55 PM
#6169   NICE "AEPP" 6% GAIN TODAY!!! Rat Fink 06/21/17 09:32:10 PM
#6168   Looks Good! Heyhey44 06/21/17 03:51:18 PM
#6167   Thanks Sage!!! arbytrader 06/21/17 03:46:25 PM
#6166   This should work! Sage7243 06/21/17 03:07:51 PM
#6165   I'm not really certain as to what stock laraz5 06/21/17 02:23:38 PM
#6164   Happens quite frequently....100 shares here and there during DayDreeming 06/21/17 02:17:40 PM
#6163   So they popped the PPS start of the laraz5 06/21/17 02:10:10 PM
#6162   Link says page not found Heyhey44 06/21/17 01:44:37 PM
#6160   Agreed Billydakidd 06/21/17 11:51:50 AM
#6159   HOUSTON, TX, April 6, 2017 / -- ONCOLIX, DayDreeming 06/21/17 09:43:57 AM
#6157   BIOPHARMA COMPANY "ONCOLIX" HAS "8" U.S. PATENTS!!! https://www.oncolixbio.com/o Rat Fink 06/21/17 09:41:41 AM
PostSubject